Eli Lilly (LLY) has signed a deal with AI startup profluent worth up to USD 2.25bln to find new ways to edit DNA

Eli Lilly's significant investment in AI startup Profluent highlights a strategic push into advanced biotechnology, particularly in DNA editing. This partnership could enhance LLY’s research capabilities and pipeline, potentially impacting its competitive edge in the pharmaceutical sector. Investors will be keen to assess the deal's long-term benefits against its cost, as well as broader implications for peers in biotechnology and life sciences.